The ergot alkaloid 2-bromo-alpha-ergocryptine and its effect on lactation in rats were first described by E. Fluckiger and H.R. Wagner in the journal Experientia (1968, no. 24). At first, this work did not attract much attention, but after isolating pure prolactin and establishing its physiological role, the high effectiveness of bromocriptine in the treatment of hyperprolactinemia soon became clear. Bromocriptine was actively studied not only by Western scientists but also in the Soviet Union beginning in 1975. The drug was used against persistent lactorrhea and amenorrhea, as well as acromegaly syndrome, and was also experimentally prescribed for Itsenko–Cushing’s disease. It was in Russia that unique data were collected on children of mothers with hyperprolactinemia who received bromocriptine therapy. Bromocriptine made an enormous contribution to the treatment of Parkinson’s disease, for which it has been used since the 1960s. In 2009, low-dose bromocriptine was approved for the treatment of type-2 diabetes. Currently, studies are continuing on the effect of this drug on various metabolic pathways (for example, gluconeogenesis, lipogenesis, etc.). Even 50 years after the discovery of bromocriptine, not all of its effects have been well studied, and researchers and doctors are facing new questions.

中文翻译：

---

溴隐亭五十年

E. Fluckiger 和 HR Wagner 在 Experientia 杂志（1968 年，第 24 期）中首次描述了麦角生物碱 2-溴-α-麦角隐碱及其对大鼠泌乳的影响。起初，这项工作并没有引起太大的关注，但在分离出纯催乳素并确立其生理作用后，溴隐亭治疗高催乳素血症的高效性很快就显现出来。溴隐亭不仅受到西方科学家的积极研究，而且从 1975 年开始在苏联也得到了积极研究。该药物用于治疗持续性乳溢和闭经，以及肢端肥大症，并且还被用于治疗伊森科-库欣病的实验处方。正是在俄罗斯，收集了有关接受溴隐亭治疗的高催乳素血症母亲的孩子的独特数据。溴隐亭为帕金森氏病的治疗做出了巨大贡献，自 1960 年代以来一直用于治疗帕金森病。2009 年，小剂量溴隐亭被批准用于治疗 2 型糖尿病。目前，正在继续研究这种药物对各种代谢途径（例如，糖异生、脂肪生成等）的影响。即使在发现溴隐亭 50 年后，也并非所有的作用都得到了很好的研究，研究人员和医生正面临着新的问题。